Toxic bacterial metabolites

Toxic bacterial metabolites represent a diverse and heterogeneous group of compounds produced by the microbiota or pathogenic bacteria that exert deleterious effects on host physiology. This broad category includes small molecule uremic toxins such as indoxyl sulfate and p-cresyl sulfate, which are associated with the progression of chronic kidney disease, as well as trimethylamine N-oxide (TMAO), a metabolite linked to increased cardiovascular risk (Wang et al., 2011; Niwa, 2011). Furthermore, complex molecules like lipopolysaccharides (LPS) act as potent endotoxins that trigger systemic inflammatory responses through the activation of Toll-like receptors (Vaziri et al., 2016). Because these metabolites are products of bacterial metabolism rather than specific host proteins, they are not classical drug targets; instead, they are addressed through sequestration therapies, such as the spherical carbon adsorbent AST-120, or targeted neutralization by monoclonal antibodies in the case of specific toxins like those from Clostridioides difficile (Asai et al., 2019). Managing these metabolites is a key focus in treating the metabolic complications of renal failure, heart disease, and systemic sepsis (Tang et al., 2019).

Other names

Bacterial toxinsGut-derived uremic toxinsMicrobial-derived metabolitesEndotoxinsXenometabolitesMicrobiota-derived toxins

Therapeutic strategies involve the physical sequestration and adsorption of metabolites within the gastrointestinal tract to prevent systemic absorption, or the use of monoclonal antibodies to directly neutralize specific bacterial protein toxins in the circulation.